BioAtla, Inc.

BCAB · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
100
SEC Filings

Business Summary

Overview We are a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancers. Our conditionally active biologics (CAB or CABs) capitalize on our proprietary discoveries with respect to tumor biology, enabling us to target known and widely validated tumor antigens that have previously been difficult or impossible to target. Our novel CAB therapeutic candidates exploit characteristic pH d...

Next Earnings

Q2 FY2026 — expected 2026-09-14

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionBCABdiscussed_in_filing Cybersecurity
topic_mentionBCABdiscussed_in_filing Cybersecurity
topic_mentionBCABdiscussed_in_filing Healthcare & Bio
topic_mentionBCABdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001193125-26-134499EDGAR102K words
2025-03-282024-12-310000950170-25-046217EDGAR—
2024-03-262023-12-310000950170-24-036548EDGAR—
2023-03-232022-12-310000950170-23-009551EDGAR—
2022-02-282021-12-310000950170-22-002303EDGAR—
2021-03-242020-12-310001193125-21-092812EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001193125-25-280435EDGAR61K words
2025-08-072025-06-300000950170-25-105220EDGAR—
2025-05-062025-03-310000950170-25-064594EDGAR—
2024-11-072024-09-300000950170-24-123506EDGAR—
2024-08-082024-06-300000950170-24-094164EDGAR—
2024-05-142024-03-310000950170-24-059757EDGAR—
2023-11-072023-09-300000950170-23-060389EDGAR—
2023-08-012023-06-300000950170-23-036554EDGAR—
2023-05-112023-03-310000950170-23-021358EDGAR—
2022-11-042022-09-300000950170-22-022036EDGAR—
2022-08-092022-06-300000950170-22-016149EDGAR—
2022-05-052022-03-310000950170-22-007871EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-020001193125-26-140053EDGAR1K words
2026-03-310001193125-26-134501EDGAR—
2026-03-230001193125-26-119698EDGAR—
2026-03-020001539497-26-000812EDGAR—
2026-02-090001193125-26-041852EDGAR—
2026-02-060001193125-26-041367EDGAR—
2026-01-300001193125-26-031942EDGAR—
2026-01-120001193125-26-010458EDGAR—
2025-12-310001193125-25-337646EDGAR—
2025-12-300001193125-25-337078EDGAR—

100 total filings indexed. 72 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001826892
TickerBCAB
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: f20642949fae0168b075f451960fe6c3eb1be7dc14818eb65369540804bbdfba
parent: cfef5a3b788f7c82c34e7e007f9b5235ed49d1646572d703f6232fde765770c4
content hash: 8491999ba5f9bfa8edc98589a106eba6caea72fe9027c3af356a8d3ce5a1bc8b
signed: 2026-04-13T04:43:53.640Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf